Products
Patecibart Biosimilar Monoclonal Antibody (Endothelin Receptor A) for Research
Cat No.: GMP-Bios-INN-1330
Anti-EDNRA therapeutic antibody (Pre-made Patecibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Patecibart (development codes GMA-301/Getagozumab) is a monoclonal antibody targeting EDNRA (endothelin receptor type A). It is developed by Gmax Biopharm. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1330-1mg | 1mg | 3090 |
| GMP-Bios-INN-1330-10mg | 10mg | |
| GMP-Bios-INN-1330-100mg | 100mg | |
| GMP-Bios-INN-1330-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Patecibart biosimilar, Whole mAb, Anti-EDNRA Antibody: Anti-EDNRA/Endothelin-1 receptor/Endothelin receptor type A (ET-A/ETA-R therapeutic antibody |
| INN Name | Patecibart |
| Target | EDNRA |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Gmax Biopharm |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Pulmonary arterial hypertension |
| Production | na |
| Development Tech | na |
